Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1 Inhibitor

Anticancer Res. 2023 Jun;43(6):2383-2391. doi: 10.21873/anticanres.16406.


Women with HR+HER2+ early-stage breast cancer are disadvantaged by the lack of clinical trials focused on women ≥70 years of age. In the past years, there has been increasing controversy on the use of toxic chemotherapy as standard of care treatment for early- stage HR+ HER2+ breast carcinoma in older women. With precision medicine coming of age, molecular profiling of tumors and circulating tumor DNA has identified target oncogenes that could be used in designing an optimal treatment for this group of women. This article reviews the current treatment of early-stage triple receptor positive breast cancer, the risks of chemotherapy in older women, and CCNG1, a novel biomarker in development for the use of DeltaRex-G, a CCNG1 inhibitor. Further, future perspectives for DeltaRex-G in older women with early stage CCNG1+ HR+ HER2+ breast cancer are discussed.

Keywords: CCNG1+; DeltaRex-G; Gene therapy; HER2+; HR+; early-stage breast cancer; letrozole; review; trastuzumab.

Publication types

  • Review

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Cyclin G1
  • Female
  • Humans
  • Receptor, ErbB-2*
  • Trastuzumab


  • retrovector encoding mutant anti-cyclin G1
  • Receptor, ErbB-2
  • Trastuzumab
  • CCNG1 protein, human
  • Cyclin G1